PRECIOUS METALS, DIAMONDS & GEMSTONES INVESTMENT SUMMIT THE LONDON CHAMBER OF COMMERCE AND INDUSTRY ● THURSDAY , 20 MAY 2010 www.ObjectiveCapitalConferences.com 2.40 – 3.05 Metals in Medicine - PGMs in anti-cancer treatments Prof Peter Sadler – Professor of Chemistry, University of Warwick
34
Embed
Objective Capital Precious Metals, Diamonds and Gemstones Investment Summit: Metals in Medicine - PGMs in anti-cancer treatments - Peter Sadler
Objective Capital Precious Metals, Diamonds and Gemstones Investment Summit Metals in Medicine - PGMs in anti-cancer treatments 20 May 2010 by Prof Peter Sadler - University of Warwick
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
• Activity in human cancer cell lines comparable to or better than cisplatin
• Different mechanism of action : activity against cisplatin-resistant cells
• Potentially less severe side-effects• Easy synthesis, high yields and lower cost• Potential for combination therapy
Next Steps• Structure-activity relationships• Mechanism of cancer cell cytotoxicity including cell
uptake• Activity of lead compounds in well-established in vivo
cancer models• Establish a panel of 6 lead compounds for
preclinical development• Use hepatocyte assays as indicators of low toxicity
to refine panel of compounds• Initial clinical trials.• Out license lead with initial preclinical & clinical data• License is a further Collaboration
Uni
vers
ityG
rant
s fo
r C
olla
bora
tion
Lice
nse
Historic License Deals• University deal values are often not disclosed• May 2009 - Sanofi-Aventis will pay Exelixis up front
fees of $141m for license rights to several cancer drugs– XL147 and XL765, both of which are in phase I trials – discovery of inhibitors of phosphoinositide-3 kinase for
the treatment of cancer• May 2009 - Celgene will pay GlobeImmune $40m
up front for an exclusive option– GlobeImmune's oncology programs, including GI-4000,
currently in Phase II trials for pancreatic cancer
Advances in PGM Anticancer Agents
Contacts:• Professor Peter Sadler, University of Warwick• Dr Shum Prakash, Business Development Manager